Close Menu

NEW YORK (GenomeWeb) – Sequenta and Illumina have struck an agreement to commercialize an in vitro diagnostic kit based on Sequenta's minimal residual disease detection and quantification technology.

Sequenta launched a laboratory-developed test dubbed ClonoSight last year. The test uses proprietary technology to target immune cells and measure MRD in leukemia and lymphoma patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.